How effective are the usual treatments for Crohn's disease?

Background : Details of the efficacy of the various drugs used in Crohn's disease are not readily available.

[1]  P. Gionchetti,et al.  Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease , 2005, Digestive Diseases and Sciences.

[2]  P. Rutgeerts,et al.  Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.

[3]  Rampton Ds.  Antagonist: Crohn's disease recurrence can be prevented after ileal resection. , 2002 .

[4]  P. Rutgeerts,et al.  Crohn's disease recurrence can be prevented after ileal resection , 2002, Gut.

[5]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[6]  F. Carbonnel,et al.  Smoking cessation and the course of Crohn's disease: an intervention study. , 2001, Gastroenterology.

[7]  P. Martreau.  [A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators]. , 2000, Gastroenterologie clinique et biologique.

[8]  G. Greenberg,et al.  A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease , 2000 .

[9]  W. Petritsch,et al.  Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. , 2000, Gastroenterology.

[10]  P. Rutgeerts,et al.  Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.

[11]  D. Podolsky,et al.  Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. , 1999, Hepato-gastroenterology.

[12]  A. Lavy,et al.  Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. , 1997, The American journal of gastroenterology.

[13]  M. Cottone,et al.  Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. , 1997, Gastroenterology.

[14]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[15]  A. Prada,et al.  Controlled trial of oral 5‐aminosalicylic acid for the prevention of early relapse in Crohn's disease , 1997, Alimentary pharmacology & therapeutics.

[16]  R. Fedorak,et al.  A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. , 1997, Gastroenterology.

[17]  B. Scott,et al.  Dietary treatment of active Crohn's disease , 1997, BMJ.

[18]  S. Targan,et al.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.

[19]  J. Belaiche,et al.  Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. , 1996, Gastroenterology.

[20]  M. Vatn,et al.  Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease , 1995, Alimentary pharmacology & therapeutics.

[21]  M. Gerig,et al.  A controlled double blind study of azathioprine in the management of Crohn's disease. , 1995, Gut.

[22]  Z. Cohen,et al.  Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. , 1995, Gastroenterology.

[23]  A. Lavie,et al.  A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. , 1995, Journal of clinical gastroenterology.

[24]  Loyd,et al.  Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. , 1995, The New England journal of medicine.

[25]  M. Scribano,et al.  Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. , 1995, Gastroenterology.

[26]  A. Zinsmeister,et al.  A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. , 1994, Journal of clinical gastroenterology.

[27]  G. Greenberg,et al.  Oral Budesonide for Active Crohn's Disease , 1994 .

[28]  D. Jewell,et al.  A comparison of budesonide with prednisolone for active Crohn's disease. , 1994, The New England journal of medicine.

[29]  J. Singleton.  Second trial of mesalamine therapy in the treatment of active Crohn's disease. , 1994, Gastroenterology.

[30]  K. Mohandas,et al.  Abdominal radiotherapy and chronic pancreatitis. , 1994, Gastroenterology.

[31]  G. Corrao,et al.  Oral mesalazine (5‐aminosalicylic acid; Asacol) for the prevention of post‐operative recurrence of Crohn's disease , 1994, Alimentary pharmacology & therapeutics.

[32]  G. Parisi,et al.  Long-term therapy with 5-aminosalicylic acid in Crohn's disease: is it useful? Our four years experience. , 1994, International journal of clinical pharmacology research.

[33]  G. Greenberg,et al.  Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. , 1994, The New England journal of medicine.

[34]  G. Hommel,et al.  Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. , 1993, Gastroenterology.

[35]  S. Hanauer,et al.  Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. , 1993, Gastroenterology.

[36]  R. Modigliani,et al.  Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID) , 1993, Gastroenterology.

[37]  C. Prantera,et al.  Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease , 1992 .

[38]  S. Hanauer,et al.  Double blind, placebo controlled trial of metronidazole in Crohn's disease. , 1991, Gut.

[39]  Coated oral 5‐aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease , 1990, Alimentary Pharmacology and Therapeutics.

[40]  D. Jewell,et al.  Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease. , 1990, Digestion.

[41]  J. Rask-Madsen,et al.  5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. , 1987, Scandinavian journal of gastroenterology.

[42]  K. Ewe,et al.  European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. , 1984, Gastroenterology.

[43]  B. Huitfeldt,et al.  A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. , 1982, Gastroenterology.

[44]  G. T. ten Velde,et al.  Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study. , 1981, Gut.

[45]  B. Pasternack,et al.  Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. , 1980, The New England journal of medicine.

[46]  R. Summers,et al.  National Cooperative Crohn's Disease Study: results of drug treatment. , 1979, Gastroenterology.

[47]  J. Lennard-jones,et al.  DOUBLE-BLIND WITHDRAWAL TRIAL OF AZATHIOPRINE AS MAINTENANCE TREATMENT FOR CROHN'S DISEASE , 1978, The Lancet.

[48]  J. Lennard-jones,et al.  Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial. , 1977, Gut.

[49]  H. Spiro,et al.  Treatment of Crohn's disease with azathioprine: a controlled evaluation. , 1974, Gastroenterology.

[50]  G. Keele.  Letter: Rubella vaccination. , 1973, Lancet.

[51]  D. Bainton,et al.  Controlled trial of azathioprine in Crohn's disease. , 1971, Lancet.

[52]  A. Dawson,et al.  Controlled trial of azathioprine in Crohn's disease. , 1971, Lancet.